Prof Daria Mochly-Rosen: TRANSLATING FUNDEMENTAL RESEARCH DISCOVERIES TO CLINICAL IMPACT
Location:H70, Abercrombie Business School: ABS Case Study Lecture Theatre 1070
To celebrate the launch of SYDNEY SPARK we invite you to attend a keynote seminar by Daria Mochly-Rosen, Professor of Chemical and Systems Biology and the George D. Smith Professor for Translational Medicine at Stanford University School of Medicine.
Professor Daria Mochly-Rosen founded the SPARK program in 2006 to provide a cost-effective model to generate proof of concept using industry standards. Since its founding, SPARK has advanced scores of new diagnostics and drugs to the clinic and commercial sectors and educated hundreds of faculty, postdoctoral fellows, and students on the translational process. She leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists and has used her basic research discoveries to develop a number of drug leads for human diseases with a particular interest in mitochondrial biology and pathology. Dr Mochly-Rosen served on many university leadership committees, was chair of her department (2001-2004) and the Senior Associate Dean for Research, Stanford University School of Medicine (between 2006 and 2013). She has published over 240 papers and over 30 patents and patent applications and has founded three companies: KAI Pharmaceuticals (2003-2011), ALDEA (now Aviv Therapeutics; 2013-) and Mitoconix (2016-).
SPARK SYDNEY emulates the successful SPARK program run at Stanford University Medical School for the past 12 years, whilst working within and capitalising on the areas of recognised expertise in Sydney at The University of Sydney and University of Technology Sydney and Macquarie University.
Date: Thursday 29 Nov 2018
Location: H70, Abercrombie Business School: ABS Case Study Lecture Theatre 1070
Seminar and networking lunch